Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
Larimar Therapeutics | DEF 14A: Definitive information statements
Larimar Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Larimar Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Larimar Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
No Data
No Data